Navigation Links
Boehringer Ingelheim Presents First Data for Tiotropium in Adolescents with Moderate Persistent Asthma
Date:5/22/2012

ns, a significant number of patients still remain symptomatic," said Dr. Christian Vogelberg, of University Children's Hospital, Dresden, Germany and lead author of the study. "As the first available data looking at tiotropium in adolescents with asthma, these results warrant further investigation into the utility of tiotropium when added to inhaled corticosteroids in this patient population."

The most commonly reported adverse events included nasopharyngitis and asthma. These results are consistent with the previous Phase II proof of concept studies demonstrating clinical activity of tiotropium in adult patients with asthma.

"We are encouraged by these Phase II trial results in moderate, persistent asthma as we continue our Phase III clinical trial program," said Tunde Otulana, MD, Vice President, Clinical Development and Medical Affairs, Respiratory, Boehringer Ingelheim Pharmaceuticals, Inc. "Our goal is to develop a treatment option for patients who still experience asthma symptoms on current therapy."

About UniTinA-Asthma™
The comprehensive Phase III trial program UniTinA-asthma™ includes a number of clinical trials in adults, adolescents and pediatric patients across different asthma severities who remain symptomatic/uncontrolled on current treatment with inhaled corticosteroids. The program includes over 4,000 patients in more than 150 sites globally.

About Asthma
Asthma is a chronic disease characterised by airway inflammation and bronchoconstriction. When a person with asthma comes into contact with an asthma trigger (e.g., infections, pollen, smoke), their airways can become inflamed, swollen and constricted, and excess mucus is produced. These reactions cause the airways to become narrower and irritated, making it difficult to breathe. People suffering from asthma experience recurrent episodes of wheezing, breathlessness, chest tightness and coughing.

As of May 2011, an estimated 235 m
'/>"/>

SOURCE Boehringer Ingelheim
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Results of Phase II Study of Boehringer Ingelheims Investigational Bronchodilator for COPD Presented at 2012 ATS International Conference
2. Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012
3. New Data to be Presented at the Annual American Thoracic Society International Conference Demonstrates Depth of Boehringer Ingelheim Respiratory Research Pipeline
4. Boehringer Ingelheim Announces Launch of GLORIA™-AF Registry in Newly-Diagnosed Patients with Non-Valvular Atrial Fibrillation
5. Phase 2b Study of Boehringer Ingelheims Interferon-Free Hepatitis C Treatment Shows Undetectable Virus in HCV Genotype-1 Patients 12 Weeks After Treatment Ended (SVR12)
6. Boehringer Ingelheim and Lillys new oral type 2 diabetes treatment for adults, Jentadueto™ (linagliptin/metformin hydrochloride) tablets, now available in U.S. pharmacies
7. Boehringer Ingelheim and Xencor Enter a Collaboration Agreement for the Development, Manufacture, and Supply of Biosuperior Monoclonal Antibodies
8. CompleGen Announces Successful Delivery of Its XenoGene™ Technology to Boehringer Ingelheim for Drug Discovery Under a Non-Exclusive Agreement.
9. AbGenomics International, Inc. Regains Global Rights to AbGn-168H from Boehringer Ingelheim
10. Boehringer Ingelheim Invests More Than $350 Million in 2011 U.S. Expansion Projects
11. Positive Interim Results from Interferon-Free Phase 2b SOUND-C2 Study with Boehringer Ingelheims Two Investigational HCV Direct Acting Antivirals Presented at AASLD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... 2, 2015   Voalte , the leader in ... of $17 million by Ascension Ventures , Cerner ... Funding. Series D funding closed on July 27, 2015, ... $60 million in three years. The new ... trajectory for Voalte. The privately held company grew revenue ...
(Date:9/2/2015)... , Sept. 2, 2015 The acute ... marketed branded drugs and hundreds of generics. While generic ... of branded therapeutics is expected to increase to more ... the development and launch of novel pipeline products between ... is the largest in terms of revenues, driven primarily ...
(Date:9/1/2015)... 2, 2015 The latest ... clinical trials review of H2, 2015 provides an ... objective to enhance decision making capabilities of active ... on Keratoconus market clinical trials review spread across ... / government organizations and supported with 43 tables ...
Breaking Medicine Technology:Voalte Raises $17 Million in Series D Financing 2Voalte Raises $17 Million in Series D Financing 3Voalte Raises $17 Million in Series D Financing 4Branded Acute Coronary Syndrome Therapies to Grab Market Share from Generic Drugs Globally 2Branded Acute Coronary Syndrome Therapies to Grab Market Share from Generic Drugs Globally 3Keratoconus Market Clinical Trials Review H2 2015 Global Research Report 2Keratoconus Market Clinical Trials Review H2 2015 Global Research Report 3Keratoconus Market Clinical Trials Review H2 2015 Global Research Report 4Keratoconus Market Clinical Trials Review H2 2015 Global Research Report 5
... With exciting new educational resources, facts and figures, and fresh ... Memorial Blood Centers today announced the official launch of its ... "As we continually strive to be the community resource ... and medical support services they need to save and sustain ...
... WHO/ WHAT:   As part of an inspirational nationwide tour, ... type 1 diabetes at age 36, will be at The Medicine ... 4:00 pm. He will speak to patients at 3:00 ... free glucose screenings to attendees. The Medicine Stop is a ...
Cached Medicine Technology:Memorial Blood Centers Launches New Online Resource 2Memorial Blood Centers Launches New Online Resource 3Ironman Competitor with Diabetes Encourages Others to Live Without Limits; Inspiring Triathlete Participates in Health Fair at The Medicine Stop 5525 South Pulaski Road, Chicago Thursday, August 26, 2010, 1:00 pm - 4:00 pm 2
(Date:9/2/2015)... Las Vegas, NV (PRWEB) , ... September 02, ... ... Las Vegas and Fort Lauderdale, CENTURION SERVICE GROUP is internationally known as an ... largest medical auction house in the world, selling more than 100,000 pieces of ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... helping to bring awareness to International Overdose Awareness Day. The goal is to ... recognize the warning signs so that they may get help. , ...
(Date:9/2/2015)... ... 2015 , ... Please join the world renowned Brain Aneurysm ... established by the Foundation in 2007 with the help of Massachusetts State Representative ... remains our top priority,” commented Christine Buckley, Executive Director of the Brain Aneurysm ...
(Date:9/2/2015)... , ... September 02, 2015 , ... ... of Breast Cancer Awareness Month (BCAM), Bright Pink, a national non-profit focused on ... will launch Act On Facts, a campaign to educate women to be breast ...
(Date:9/1/2015)... ... September 01, 2015 , ... An August 25 ... of plastic surgeries conducted each year on teenagers, quoting a New York City-area ... Beverly Hills-based plastic surgeon Payam Jarrah-Nejad, M.D., F.I.C.S., F.A.C.S., known more familiarly to ...
Breaking Medicine News(10 mins):Health News:Over 1800 Lots of Surplus Used Medical Equipment 2Health News:Over 1800 Lots of Surplus Used Medical Equipment 3Health News:August 31 is International Overdose Awareness Day – Lakeview Health to Help Bring Awareness 2Health News:September Celebrated as Brain Aneurysm Awareness Month 2Health News:Bright Pink Launches Act On Facts™, A Campaign To Empower Young Women To Take Action Related To Their Breast And Ovarian Health 2Health News:Bright Pink Launches Act On Facts™, A Campaign To Empower Young Women To Take Action Related To Their Breast And Ovarian Health 3Health News:Teen Plastic Surgery Article Understates the Most Important Realities of Procedures on Young People, Notes Dr. J 2
... January 12, 2010 (BRONX, NY) Older women ... lesions that cause dementia later in life, according to ... The findings were published in the December 2009 online ... The research was conducted as part of the ...
... WINSTON-SALEM, N.C. A fast-acting compound that appears to ... found in patients with progressive Alzheimer,s disease has been ... Medicine and the Vanderbilt University Medical Center Program in ... result in humans. The compound benzylquinolone carboxylic ...
... ... Molecular Medicine. Molecular Medicine publishes research concerned with the pathogenesis of disease at the ... prevention. , ... January 12, 2010 -- By the time a person experiences symptoms of an aggressive ...
... , DETROIT , Jan. 12 ... Board of Directors has set the date for the Company,s Annual Meeting ... vote at the meeting.   , The Annual Shareholders, Meeting will be ... EST at the MGM Grand Hotel, 1777 Third Street in ...
... hospice and preferred place of death are often needed, experts ... patients have much to consider, from whether they want to ... want doctors to continue aggressive treatment or focus on making ... those difficult, emotional conversations aren,t happening nearly as often, or ...
... WASHINGTON , Jan. 12 The American Lung ... report, which grades the strength of federal and state ... at the heart of America,s chronic disease crisis. , The ... still has significant room for progress. Most state governments , ...
Cached Medicine News:Health News:Hypertension linked to dementia in older women 2Health News:Hypertension linked to dementia in older women 3Health News:New compound improves cognitive decline, symptoms of Alzheimer's disease in rodents 2Health News:New compound improves cognitive decline, symptoms of Alzheimer's disease in rodents 3Health News:News from the Latest Issue of Molecular Medicine 2Health News:United American Healthcare Corporation Announces Meeting Date and Record Date for Annual Meeting of Shareholders 2Health News:United American Healthcare Corporation Announces Meeting Date and Record Date for Annual Meeting of Shareholders 3Health News:Doctors Put Off End-of-Life Talks With Terminally Ill 2Health News:Doctors Put Off End-of-Life Talks With Terminally Ill 3Health News:American Lung Association Report Card: Federal Government Makes Major Strides; Most States Flunk for Neglecting to Prevent Tobacco-Caused Disease 2Health News:American Lung Association Report Card: Federal Government Makes Major Strides; Most States Flunk for Neglecting to Prevent Tobacco-Caused Disease 3Health News:American Lung Association Report Card: Federal Government Makes Major Strides; Most States Flunk for Neglecting to Prevent Tobacco-Caused Disease 4Health News:American Lung Association Report Card: Federal Government Makes Major Strides; Most States Flunk for Neglecting to Prevent Tobacco-Caused Disease 5Health News:American Lung Association Report Card: Federal Government Makes Major Strides; Most States Flunk for Neglecting to Prevent Tobacco-Caused Disease 6Health News:American Lung Association Report Card: Federal Government Makes Major Strides; Most States Flunk for Neglecting to Prevent Tobacco-Caused Disease 7Health News:American Lung Association Report Card: Federal Government Makes Major Strides; Most States Flunk for Neglecting to Prevent Tobacco-Caused Disease 8
3.2% Tryptone, 2.0% Yeast Extract, 0.5% Sodium Chloride, pH 7.5....
... Evolve™ modular radial head system employs the ... research to create the next generation of ... two part, modular design, the implant system ... match the patients anatomy. In addition, the ...
For connection to the bipolar output of electrosurgical generators....
Recommended for use with spark gap coagulators for added safety. Also available in stainless steel (10-3002)....
Medicine Products: